Treosulfan

Orphan DrugFDA Approved (2025)

Description

An alkylating agent used with fludarabine as conditioning before allogeneic hematopoietic stem cell transplantation in AML or MDS. FDA-approved January 2025.

Indications & Therapeutic Use

Conditioning for allogeneic HSCT (AML/MDS)

Global Availability (1 countries)

CountryAccess RouteRegulatory PathwayLead TimeStatus
Standard Marketing AuthorizationApproved

Buy / Source Treosulfan — GNH India

26 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.

Browse all Treosulfan products on GNH India

Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.

Available Through

This drug is available for procurement through the following fulfilment partner.

Fulfilment Partner
Treosulfan
Generic Nametreosulfan
Brands1 brand available
Active Ingredienttreosulfan
Drug ClassConditioning for allogeneic HSCT (AML/MDS)
Manufacturermedac
Medical CodeL01AB02
Orphan StatusYes — Orphan Drug
Cold ChainNot Required
Reg. StatusFDA Approved (2025)
Countries1 countries
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes